Linked Life Data

18523294

Source:http://linkedlifedata.com/resource/pubmed/id/18523294

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2008-6-4
pubmed:abstractText
Sudden exposure of human populations to chemicals, pathogens, or radiation has the potential to result in substantial morbidity. A potential means of rapidly protecting such populations might be to activate innate host defense pathways, which can provide broad protection against a variety of insults. However, innate immune activators can, by themselves, result in severe inflammatory pathology, which in large part is driven by hemopoietic-derived cytokines such as TNF-alpha. We reasoned that, because it preferentially activates epithelial cells, the TLR5 agonist flagellin might not induce severe inflammatory pathology and yet be an ideal agent to provide such non-specific protection, particularly at the mucosal surfaces that serve as a front line of host defense. In accordance, we observed that systemic treatment of mice with purified flagellin did not induce the serologic, histopathologic, and clinical hallmarks of inflammation that are induced by LPS but yet protected mice against chemicals, pathogens, and ionizing radiation. Flagellin-elicited radioprotection required TLR5, the TLR signaling adaptor MyD88, and was effective if given between 2 h before to 4 h after exposure to irradiation. Flagellin-elicited radioprotection was, in part, mediated via effects on cells in bone marrow but yet rescued mortality without a pronounced rescue of radiation-induced anemia or leukopenia. Thus, systemic administration of flagellin may be a relatively safe means of providing temporary non-specific protection against a variety of challenges.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
180
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
8280-5
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:18523294-Administration, Oral, pubmed-meshheading:18523294-Animals, pubmed-meshheading:18523294-Cytokines, pubmed-meshheading:18523294-Dextran Sulfate, pubmed-meshheading:18523294-Flagellin, pubmed-meshheading:18523294-Gamma Rays, pubmed-meshheading:18523294-Immunity, Innate, pubmed-meshheading:18523294-Injections, Intraperitoneal, pubmed-meshheading:18523294-Lipopolysaccharides, pubmed-meshheading:18523294-Mice, pubmed-meshheading:18523294-Mice, Inbred BALB C, pubmed-meshheading:18523294-Mice, Inbred C57BL, pubmed-meshheading:18523294-Mice, Knockout, pubmed-meshheading:18523294-Myeloid Differentiation Factor 88, pubmed-meshheading:18523294-Radiation-Protective Agents, pubmed-meshheading:18523294-Rotavirus Infections, pubmed-meshheading:18523294-Salmonella Infections, Animal, pubmed-meshheading:18523294-Toll-Like Receptor 5
pubmed:year
2008
pubmed:articleTitle
Flagellin treatment protects against chemicals, bacteria, viruses, and radiation.
pubmed:affiliation
Department of Pathology, Emory University, Atlanta, GA 30322, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural